Cartography Biosciences secured $67 million in a Series B funding round led by Pfizer Ventures to advance its lead candidate targeting colorectal cancer. The biotech develops bispecific and multispecific antibody therapeutics using platform technologies distinguishing cancer cells through analyses comparing healthy and diseased tissues. The infusion of capital accelerates clinical development efforts and future pipeline expansion, supported by recent collaboration with pharmaceutical firms such as Amgen. This financing round underscores continued investor confidence in innovative immuno-oncology approaches for commonly diagnosed cancers.